Cellectar Biosciences
CLRB
CLRB
45 hedge funds and large institutions have $36.3M invested in Cellectar Biosciences in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0.14% more ownership
Funds ownership: 2.34% → 2.48% (+0.14%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
81% less call options, than puts
Call options by funds: $93K | Put options by funds: $499K
Holders
45
Holding in Top 10
1
Calls
$93K
Puts
$499K
Top Buyers
| 1 | +$3.54M | |
| 2 | +$2.82M | |
| 3 | +$2.08M | |
| 4 |
Barclays
London,
United Kingdom
|
+$1.35M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$984K |
Top Sellers
| 1 | -$5.51M | |
| 2 | -$2.93M | |
| 3 | -$1.92M | |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.33M |
| 5 |
Morgan Stanley
New York
|
-$35.4K |